ACUMEN PHARMACEUTICALS INC
ABOSNASDAQTrading Snapshot
- Day Range
- $2.23 – $2.27
- 52-Week Range
- $1.50 – $3.60
- Volume
- $5.03B
- Avg Volume
- $5.64B
- Shares Outstanding
- 72.2M
- Next Earnings
- Nov 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $15M
- Last Q Revenue
- $4M
- P/E Ratio
- -1.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.45
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.9%
Why Investors Own ABOS
- ✓High-growth profile — revenue up +11.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 56% gross margin and 4% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ACUMEN PHARMACEUTICALS INC
ABOS
StockOtter · stockotter.spaceAbout ACUMEN PHARMACEUTICALS INC
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic solub
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
NEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for
ADAR1 Capital Management LLC Makes New Investment in Acumen Pharmaceuticals, Inc. $ABOS
ADAR1 Capital Management LLC acquired a new position in shares of Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange